Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. April 2026 10:30 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S....
21. April 2026 00:30 ET | Quelle: Custom Market Insights

[Latest] Global Surgical Drill Bits Market Size/Share Worth USD 540 Million by 2035 at a 5.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, April 21, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Surgical Drill Bits Market Size, Trends and Insights By Type (Standard Solid...
20. April 2026 08:00 ET | Quelle: Kyverna Therapeutics, Inc.

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial Totality of efficacy and safety data reinforces miv-cel’s...
20. April 2026 08:00 ET | Quelle: Amneal Pharmaceuticals LLC

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsDemonstrated substantial increases in daily “Good On” time,...
20. April 2026 08:00 ET | Quelle: Genius Group Limited

Genius Group Receives ICC Arbitration Award, Wins Return of 7.4 Million Shares and $8.0 Million Cash Payment

SINGAPORE, April 20, 2026 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) ("Genius Group" or the "Company"), a leading AI-powered education group, today announced that it has received...
20. April 2026 06:00 ET | Quelle: Howard Hughes Holdings Inc.

Howard Hughes Holdings Appoints Former Arch Capital CEO Marc Grandisson to Company’s Board of Directors

THE WOODLANDS, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc. (NYSE: HHH) (“the Company” or “Howard Hughes”) today announced the appointment of Marc Grandisson to its Board of...
20. April 2026 04:20 ET | Quelle: Research and Markets

Anti-aging Drugs for Dogs Analysis Report 2025: Market to Reach $5.34 Billion by 2035 - Close to 15 Therapies are Currently Being Investigated Across Various Stages of Development

Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Anti-aging Drugs for Dogs Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Molecule, Type of Biologic, Route of...
20. April 2026 04:00 ET | Quelle: Oculis Holding AG

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A...
20. April 2026 04:00 ET | Quelle: Oculis Holding AG

Oculis lýkur síðustu eftirfylgniheimsókn í fasa 3 DIAMOND rannsóknaráætluninni með OCS-01 augndropum til meðferðar á sjónhimnubjúg af völdum sykursýki

ZUG, Sviss, April 20, 2026 (GLOBE NEWSWIRE) -- Síðustu eftirfylgniheimsóknunum í báðum OCS-01 fasa 3 DIAMOND rannsóknaráætlununum (alls 800+ sjúklingar) er lokið og búist er við helstu niðurstöðum í...
20. April 2026 04:00 ET | Quelle: Oculis Holding AG

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema...

Vorherige Seite

Nächste Seite